HuP-T4Homo sapiens (Human)Cancer cell line

Also known as: HUPT4, HuPT4, Hu-P-T4, HUP-T4

🤖 AI SummaryBased on 12 publications

Quick Overview

Human pancreatic carcinoma cell line with high CEA and CA19-9 secretion.

Detailed Summary

HuP-T4 is a human pancreatic carcinoma cell line established from the ascites of a patient with carcinomatous peritonitis. It exhibits a population doubling time of 37.1 hours and secretes significant amounts of CEA and CA19-9 into the culture medium. The cell line shows tumorigenicity in mice, forming well-differentiated papillotubular adenocarcinoma. Immunocytochemical analysis reveals distinct expression patterns of intermediate filaments and other markers, indicating its epithelial origin. HuP-T4 is valuable for studying pancreatic cancer biology and therapeutic responses.

Research Applications

Cancer biologyDrug developmentTumor marker analysis

Key Characteristics

High CEA and CA19-9 secretionTumorigenic in miceWell-differentiated papillotubular adenocarcinoma formationEpithelial origin

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1300
Species	Homo sapiens (Human)
Tissue Source	Ascites[UBERON:UBERON_0007795]

Donor Information

Age	60
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Pancreatic adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	DSMZ
Source ID	ACH-000213_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Ile255Thr (c.764T>C)	Homozygous	-	Unknown, Unknown
MutationSimple	KRAS	p.Gly12Val (c.35G>T)	Heterozygous	Acquired	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

10,12

D13S317

D16S539

10,11

D18S51

D19S433

D21S11

29,32.2

D2S1338

18,19

D3S1358

D5S818

10,11

D7S820

8,11

D8S1179

11,16

FGA

23,24,25

Penta D

Penta E

18,19

TH01

TPOX

vWA

17,18

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOI PubMed PMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOI PubMed PMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

DOI PubMed PMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOI PubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOI PubMed

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.

Linnartz R., Zubel A., Slamon D.J., Finn R.S.

Br. J. Cancer 111:1788-1801(2014).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Oncogene 24:1794-1801(2005).

DOI PubMed

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Veltman J.A., van Kessel A.G., Hoglund M.

Cancer Res. 64:3052-3059(2004).

DOI PubMed

Immunocytochemical analysis of cell lines derived from solid tumors.

Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.

J. Histochem. Cytochem. 49:1369-1378(2001).

DOI PubMed

Newly established human pancreatic carcinoma cell lines and their lectin binding properties.

Yamazaki K., Watanabe A., Sasaki H.

Int. J. Pancreatol. 13:31-41(1993).

DOI PubMed

Distribution of characteristic mutations in native ductal adenocarcinoma of the pancreas and pancreatic cancer cell lines.

Saeger H.-D.

Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).

DOI